查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370970

治疗性血浆交换市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、技术、适应症、最终用户、地区和竞争细分

Therapeutic Plasma Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Technology, By Indication, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球治疗性血浆交易市场估值达到7.6201亿美元，预计在预测期内将出现强劲增长，预计复合年增长率（CAGR）为6.75%，到2028年预计将达到11.116亿美元。

主要市场驱动因素：

市场概况
预测期 2024-2028
2022 年市场规模 7.6201亿美元
2028 年市场规模 111160万美元
2023-2028 年复合年增长率 6.75%
成长最快的细分市场 神经系统疾病
最大的市场 北美洲
  • 1.神经、肾臟和血液疾病的高盛行率：慢性疾病的高盛行率，包括肾病变、急性肝衰竭、格林-巴利综合症（GBS）等，有助于整体治疗性血浆交换市场的增长。治疗性血浆置换的应用激增，同时进行了大量研究和临床试验来评估其与其他治疗方法相比的疗效。这些因素极大地促进了治疗性血浆交换市场的成长。
  • 2.治疗性血浆交换研究和开发的进展：连续流离心等高精度技术可有效分离特定的血液成分，并且正在观察技术进步，包括下一代单采设备的开发。先进的 TPE 系统最大限度地减少人工干预，提高程序效率，并促进此类系统在各种条件下的采用。
  • 3.扩大血浆交换治疗应用的多样性：多种神经系统疾病的治疗是市场成长的重要催化剂。 TPE 被认为是治疗急性发炎性脱髓鞘多发性神经根神经病变、重症肌无力 (MG) 和副肿瘤性脑病变等疾病的主要治疗方法。此外，它也被用作各种其他神经系统疾病的辅助治疗。这些神经系统疾病的盛行率持续上升，促进了市场的进步。
  • 4.生物製药公司对血浆源的需求不断增长：生物製药公司对用于治疗各种衰弱、慢性和危及生命的疾病的血浆源的需求不断增长，这是一个重要的驱动因素。血浆衍生疗法在多种疾病的治疗中发挥着至关重要的作用，促进了对血浆衍生产品的需求和血浆置换市场的成长。

主要市场挑战：

  • 1.与血浆去除术相关的风险：血浆去除术涉及从人体中提取部分血液并透过静脉注射补充液体。虽然通常被认为是安全的，但也存在相关风险，包括感染、过敏反应、低血压、内出血、电解质失衡等。这些风险可能会限制血浆置换术的广泛采用。
  • 2.治疗性血浆交换产品的高成本：治疗性血浆交换所需的专用设备（例如单采机和一次性组件）的成本导致了手术的高成本。品质控制流程和遵守行业标准进一步增加了成本。 TPE 产品的生产规模有限也会导致单位成本较高。

主要市场趋势：

  • 1.持续进步：持续的技术进步提高了患者满意度并改善了血液製品的加工。连续流离心等先进方法需要最少的血流量，这使得它们在促进血液采集方面更加先进。这些技术的发展在市场中创造了机会。
  • 2.治疗性血浆程序在儿科应用的使用：治疗性血浆交换治疗在儿科应用的研究越来越多，用于去除各种疾病中的致病物质。这包括罕见儿科疾病和自体免疫疾病的治疗，有助于市场成长。

细分洞见：

  • 1.适应症见解：由于老年族群中神经系统疾病的发生率和盛行率不断增加以及该领域正在进行的研究，预计神经系统疾病将主导市场。
  • 2.技术见解：离心技术预计将在治疗性血浆交换市场中占据重要份额，这要归功于其在供体单采术中的广泛采用，提供成本效益和高效的血浆去除。

区域见解：

北美在全球治疗性血浆交换市场中占据主导地位，自体免疫疾病的高盛行率、完善的医院基础设施以及生物技术企业的强大影响力等因素促进了其成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品（消耗品、设备）
    • 依技术分类（离心、膜分离）
    • 依适应症（神经系统疾病、血液系统疾病、肾臟疾病、代谢性疾病、其他）
    • 按最终使用者（采血中心和血液成分提供者、医院和诊所、输血中心、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲治疗性血浆交换市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按指示
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非治疗性血浆交换
    • 沙乌地阿拉伯治疗性血浆交换
    • 阿联酋治疗性血浆交换

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球治疗性血浆交换市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Asahi Kasei Corporation
    • Baxter International Inc
    • B. Braun Melsungen AG
    • Cerus Corporation
    • Fresenius Kabi AG
    • Haemonetics Corporation
    • Hemacare Corporation
    • IncMedica SpA
    • Kawasumi Laboratories
    • Terumo Corporation

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 4598

The Global Therapeutic Plasma Exchange Market reached a valuation of USD 762.01 Million in 2022 and is expected to experience robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.75% and expected to reach USD 1111.60 Million through 2028.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an advanced medical procedure used to separate pathogenic substances from patients' blood and replace them with replacement fluids, such as albumin solution or fresh frozen plasma. These substances include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is widely employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing significantly to market expansion. It also offers the significant benefit of reducing plasma viscosity and is utilized in the management of chronic diseases as a first-line or second-line therapy or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 762.01 Million
Market Size 2028USD 1111.60 Million
CAGR 2023-20286.75%
Fastest Growing SegmentNeurological Disorders
Largest MarketNorth America
  • 1. High Prevalence of Neurological, Renal, and Hematological Disorders: The high prevalence of chronic diseases, including nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. There has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.
  • 2. Advances in Therapeutic Plasma Exchange Research and Development: High-precision technologies like continuous-flow centrifugation effectively separate specific blood components, and technological advancements, including the development of next-generation apheresis devices, are being observed. Advanced TPE systems minimize manual intervention, enhance procedure efficiency, and promote the adoption of such systems for a wide range of conditions.
  • 3. Expanding Variety of Therapeutic Plasma Exchange Applications: The treatment of a wide array of neurological disorders serves as a significant catalyst for market growth. TPE is considered the primary treatment for conditions such as acute inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Additionally, it is employed as a secondary treatment for various other neurological conditions. The prevalence of these neurological disorders continues to rise, contributing to market progress.
  • 4. Increasing Demand for Source Plasma from Biopharmaceutical Companies: The growing demand for source plasma from biopharmaceutical companies for the treatment of various debilitating, chronic, and life-threatening disorders is a significant driver. Plasma-derived therapies play a crucial role in the treatment of a broad spectrum of diseases, contributing to the demand for plasma-derived products and the growth of the plasmapheresis market.

Key Market Challenges:

  • 1. Risk Associated with Plasmapheresis Procedures: Plasmapheresis procedures involve extracting a portion of blood from the human body and administering replacement fluids intravenously. While generally considered safe, there are associated risks, including infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. These risks may limit the widespread adoption of plasmapheresis.
  • 2. High Cost of Therapeutic Plasma Exchange Products: The cost of specialized equipment required for therapeutic plasma exchange, such as apheresis machines and disposable components, contributes to the high cost of the procedure. Quality control processes and compliance with industry standards further add to the cost. The limited scale of production for TPE products can also lead to higher per-unit costs.

Key Market Trends:

  • 1. Continuous Advancement: Ongoing technological advancements enhance patient satisfaction and improve the processing of blood-derived goods. Advanced methods like continuous-flow centrifugation require minimal blood flow, making them more advanced for facilitating blood collection. These technological developments create opportunities within the market.
  • 2. Use of Therapeutic Plasma Procedure in Pediatric Applications: Therapeutic plasma exchange treatments are increasingly studied for pediatric applications in the removal of pathogenic materials in various diseases. This includes the treatment of rare pediatric disorders and autoimmune diseases, contributing to market growth.

Segmental Insights:

  • 1. Indication Insights: Neurological disorders are expected to dominate the market, driven by the increasing incidence and prevalence of these diseases in the geriatric population and ongoing research in this field.
  • 2. Technology Insights: Centrifugation technology is projected to hold a significant share in the Therapeutic Plasma Exchange market, thanks to its widespread adoption in donor apheresis, offering cost-effectiveness and efficient plasma removal.

Regional Insights:

North America dominates the global therapeutic plasma exchange market, with factors such as a high prevalence of autoimmune diseases, a well-established hospital infrastructure, and a strong presence of biotech enterprises contributing to its growth.

Key Market Players

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutic Plasma Exchange Market, By Product:

  • Consumables
  • Devices

Therapeutic Plasma Exchange Market, By Technology:

  • Centrifugation
  • Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

  • Neurological Disorders
  • Haematology Disorders
  • Renal Disorders
  • Metabolic Disorders
  • Others

Therapeutic Plasma Exchange Market, By End User:

  • Blood Collection Centres & Blood Component Providers
  • Hospitals & Clinics
  • Blood Transfusion Centres
  • Others

Therapeutic Plasma Exchange Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

  • Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Devices)
    • 5.2.2. By Technology (Centrifugation, Membrane Separation)
    • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
    • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Indication
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By End User
    • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Asahi Kasei Corporation
    • 15.5.2. Baxter International Inc
    • 15.5.3. B. Braun Melsungen AG
    • 15.5.4. Cerus Corporation
    • 15.5.5. Fresenius Kabi AG
    • 15.5.6. Haemonetics Corporation
    • 15.5.7. Hemacare Corporation
    • 15.5.8. IncMedica S.p.A.
    • 15.5.9. Kawasumi Laboratories
    • 15.5.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer